Acasti Pharma Inc (ACST.O)
22 Sep 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2016||Executive Chairman of the Board|
|2017||President, Chief Executive Officer, Director|
|2016||Chief Financial Officer|
|2010||Chief Operating Officer|
|Vice President- Clinical and Non-Clinical Affairs|
- BRIEF-Acasti Pharma reports Q1 loss per share c$0.19
- BRIEF-Acasti Pharma issues common shares in payment of outstanding interest under debentures
- BRIEF-Acasti Pharma reports Q4 and FY 2017 financial results
- BRIEF-Acasti Pharma, CordenPharma announce large scale production of CaPre with new continuous manufacturing process
- BRIEF-Acasti Pharma says has successfully completed two Phase 1, two Phase 2 clinical trials with Capre